Annual report pursuant to Section 13 and 15(d)

Going Concern (Details Narrative)

v3.21.1
Going Concern (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 07, 2021
Jan. 31, 2020
Sep. 30, 2019
May 31, 2020
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Mar. 25, 2021
Cash and cash equivalents         $ 2,772       $ 2,321         $ 2,772 $ 2,321  
Accounts receivable, net         8,028       10,338         8,028 10,338  
Total current assets         14,122       16,510         14,122 16,510  
Total current liabilities         18,233       17,292         18,233 17,292  
Net loss         $ 8,143 $ 6,234 $ 5,580 $ 6,494 $ 10,663 $ 7,446 $ 5,304 $ 3,326   26,451 26,740  
Net cash used in operating activities                           $ 13,979 $ 18,957  
Sale of common stock                           178,000 97,817  
Subsequent Event [Member]                                
Debt Instrument, Interest Rate 8.00%                              
Maturity Date Jun. 30, 2021                              
Cash on hand                               $ 3,200
Secured Promissory Note [Member] | Ampersand 2018 Limited Partnership [Member] | Subsequent Event [Member]                                
Debt Instrument, Face Amount $ 3,000                              
Secured Promissory Note [Member] | 1315 Capital [Member] | Subsequent Event [Member] | Series B Shareholders [Member]                                
Debt Instrument, Face Amount $ 2,000                              
Series B Preferred Stock [Member]                                
Proceeds from public offering   $ 19,200                            
Sale of common stock   20,000                            
Equity Distribution Agreement [Member]                                
Proceeds from public offering     $ 3,700                          
ATM Agreement [Member]                                
Proceeds from public offering                           $ 700    
Sale of common stock                           178,000    
Centers for Medicare & Medicaid Services [Member]                                
Loans payable           2,100             $ 2,100      
Department of Health and Human Services [Member]                                
Loans payable           $ 650             650      
Utilization of advance payment against cash payments                         $ 2,100      
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]                                
Proceeds from loans payable       $ 888                        
Silicon Valley Bank [Member]                                
Repayment of line of credit                           $ 3,400